Grufity logoGrufity logo

Merck & Co Inc Stock Research

MRK

103.52USD-0.88(-0.84%)Market Closed

Market Summary

USD103.52-0.88
Market Closed
-0.84%

MRK Alerts

MRK Stock Price

MRK RSI Chart

MRK Valuation

Market Cap

272.8B

Price/Earnings (Trailing)

17.88

Price/Sales (Trailing)

4.63

EV/EBITDA

14

Price/Free Cashflow

13.8

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

27.74%

Return on Equity

31.57%

Return on Assets

13.3%

Free Cashflow Yield

7.24%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

59.3B

Revenue Y/Y

2.29%

Revenue Q/Q

-7.55%

MRK Earnings

Earnings (TTM)

14.5B

Earnings Y/Y

-19.72%

Earnings Q/Q

-7.11%

Price Action

52 Week Range

77.92115.49
(Low)(High)

Last 7 days

-3.6%

Last 30 days

-5.1%

Last 90 days

-7.5%

Trailing 12 Months

32.8%

MRK Financial Health

Current Ratio

1.47

MRK Investor Care

Dividend Yield

2.7%

Dividend/Share (TTM)

2.8

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

5.71

Peers (Alternatives to Merck)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
396.9B
94.9B
-4.42% -11.67%
22.12
4.18
1.25% -14.07%
298.8B
28.5B
1.30% 17.85%
47.85
10.47
0.79% 11.88%
272.8B
59.3B
-5.09% 32.83%
17.88
4.63
21.72% 11.27%
226.2B
100.3B
-5.50% -20.78%
7.21
2.25
23.43% 42.74%
142.4B
46.2B
-5.97% -4.10%
22.5
3.08
-0.49% -9.54%
MID-CAP
4.5B
4.5B
-8.55% -11.11%
-32.05
1.01
7.56% -104.06%
3.2B
2.2M
109.33% 133.59%
-10.15
1.4K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-10.48% 10.28%
30.48
2.77
15.09% 13.64%
1.6B
602.5M
-5.76% -54.20%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-20.83% -73.20%
-0.29
1.93
-31.50% -634.70%
772.8M
285.2M
-9.04% -42.36%
3.51
2.71
-27.21% -40.28%
726.9M
114.5M
-12.79% -47.96%
-4.31
6.35
27.90% 57.40%
539.5M
29.8M
-36.94% -53.16%
-6.21
18.13
340.05% 4.35%
379.1M
51.5M
-14.46% -5.94%
-5.34
7.36
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Merck

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.5%59,28358,97457,16953,97848,704
  S&GA Expenses-1.4%10,04210,18510,0019,7709,634
  R&D Expenses5.5%13,54812,84110,88712,41012,245
EBITDA-2.1%18,26818,66421,15718,246-
EBITDA Margin-2.6%0.31*0.32*0.37*0.34*-
Earnings Before Taxes-2.4%16,44416,84018,52315,75313,879
EBT Margin-2.9%0.28*0.29*0.32*0.29*-
Interest Expenses4.5%888850806--
Net Income-4.9%14,51915,26016,57914,18013,049
Net Income Margin-5.4%0.24*0.26*0.29*0.26*-
Free Cahsflow-3.4%19,09519,76018,95516,092-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.9%109,160107,081107,095106,668105,694
  Current Assets6.4%35,72233,56132,11631,18430,266
    Cash Equivalents13.9%12,69411,1459,6758,5568,096
  Inventory5.3%5,9115,6145,5355,7745,953
  Net PPE4.9%21,42220,42420,05919,74719,279
  Goodwill0.2%21,20421,16021,21321,25821,264
  Current Liabilities5.4%24,23922,99823,16822,31623,872
    LT Debt, Current-2,300----
    LT Debt, Non Current0.9%28,74528,48228,68430,58630,690
Shareholder's Equity3.4%45,99144,45843,31840,95338,184
  Retained Earnings1.9%61,08159,92858,43756,25253,696
  Additional Paid-In Capital0.3%44,37944,24344,11544,27544,238
Accumulated Depreciation0.4%17,98517,92117,79818,49818,192
Minority Interest1.5%67.0066.0075.0070.0073.00
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-3.4%19,09519,76018,95516,64313,122
  Share Based Compensation5.0%541515493488479
Cashflow From Investing67.5%-4,960-15,261-15,360-16,908-16,421
Cashflow From Financing-286.7%-9,119-2,358-1,9302,1093,097
  Dividend Payments1.5%7,0126,9056,8076,7106,610
  Buy Backs-100.0%0.0036.001,202840-

Risks for MRK

What is the probability of a big loss on MRK?

16.5%


Probability that Merck stock will be more than 20% underwater in next one year

0%


Probability that Merck stock will be more than 30% underwater in next one year.

0%


Probability that Merck stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.

Drawdowns

Returns for MRK

Cumulative Returns on MRK

12.9%


10-Year Cumulative Returns

14.1%


7-Year Cumulative Returns

18.6%


5-Year Cumulative Returns

21.3%


3-Year Cumulative Returns

What are the long-term rolling returns for MRK?

FIve years rolling returns for Merck.

Annualized Returns

Which funds bought or sold MRK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
0.12
4,918,200
21,436,200
0.60%
2023-03-13
Claro Advisors LLC
added
30.13
439,275
1,192,280
0.39%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-2.09
89,259,000
430,663,000
0.47%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
3,421
16,421
-%
2023-03-10
MATHER GROUP, LLC.
added
3.46
765,244
3,065,240
0.06%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-0.43
586,661
2,660,660
0.42%
2023-03-08
Capital Asset Advisory Services LLC
added
1.33
593,991
2,345,990
0.19%
2023-03-07
Great Lakes Retirement, Inc.
new
-
565,897
565,897
0.14%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-2.95
1,153,190
5,758,190
2.19%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
14.45
458,334
1,423,330
0.09%

1–10 of 47

Latest Funds Activity

Are funds buying MRK calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MRK
No. of Funds

Merck News

Best Stocks

Darwin Wealth Management LLC Increases Its Position in Merck & ....

Best Stocks,
4 hours ago

Investors Chronicle

Is the US the answer in the search for income?.

Investors Chronicle,
17 hours ago

StockNews.com

Nasdaq

Financial Advisor Magazine

Yahoo Finance

The Motley Fool

Schedule 13G FIlings of Merck

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.96%
227,205,978
SC 13G/A
Feb 03, 2023
blackrock inc.
8.5%
215,011,385
SC 13G/A
Feb 09, 2022
vanguard group inc
8.36%
211,202,531
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
198,224,264
SC 13G/A
Feb 10, 2021
vanguard group inc
8.24%
208,410,644
SC 13G/A
Feb 05, 2021
blackrock inc.
7.8%
196,213,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.26%
210,542,333
SC 13G/A
Feb 05, 2020
blackrock inc.
7.5%
190,783,225
SC 13G/A

MRK Fair Value

Recent SEC filings of Merck

View All Filings
Date Filed Form Type Document
Feb 24, 2023
10-K
Annual Report
Feb 16, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 13, 2023
4
Insider Trading
Feb 10, 2023
4
Insider Trading
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
4
Insider Trading
Feb 06, 2023
4
Insider Trading
Feb 03, 2023
SC 13G/A
Major Ownership Report
Feb 02, 2023
8-K
Current Report

Latest Insider Trading transactions for MRK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-15
Romanelli Joseph
sold
-541,100
108
-5,000
president, human health int?l
2023-02-13
MIZELL STEVEN
sold
-198,017
109
-1,815
evp, chief hr officer
2023-02-10
Williams David Michael
acquired
128,598
106
1,205
evp,chief info&digital officer
2023-02-10
Williams David Michael
sold (taxes)
-44,075
106
-413
evp,chief info&digital officer
2023-02-09
MIZELL STEVEN
sold
-535,006
107
-5,000
evp, chief hr officer
2023-02-06
MIZELL STEVEN
sold
-462,473
104
-4,436
evp, chief hr officer
2023-02-03
Zachary Jennifer
sold
-7,782,760
103
-75,436
evp, general counsel
2023-02-03
Zachary Jennifer
acquired
4,227,430
56.04
75,436
evp, general counsel
2023-01-23
Davis Robert M
acquired
2,661,730
109
24,224
ceo & president
2023-01-23
Chattopadhyay Sanat
acquired
1,922,350
109
17,495
exe v-p & pres. mmd

1–10 of 50

About Merck

MRK Income Statement

2022-12-31
Consolidated Statement of Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Sales$ 59,283$ 48,704$ 41,518
Costs, Expenses and Other   
Cost of sales17,41113,62613,618
Selling, general and administrative10,0429,6348,955
Research and development13,54812,24513,397
Restructuring costs337661575
Other (income) expense, net1,501(1,341)(890)
Total costs, expenses and other42,83934,82535,655
Income from Continuing Operations Before Taxes16,44413,8795,863
Taxes on Income from Continuing Operations1,9181,5211,340
Net Income from Continuing Operations14,52612,3584,523
Less: Net Income Attributable to Noncontrolling Interests7134
Net Income from Continuing Operations Attributable to Merck & Co., Inc.14,51912,3454,519
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests07042,548
Net Income Attributable to Merck & Co., Inc.$ 14,519$ 13,049$ 7,067
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders   
Income from Continuing Operations (in dollars per share)$ 5.73$ 4.88$ 1.79
Income from Discontinued Operations (in dollars per share)00.281.01
Net Income (in dollars per share)5.735.162.79
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders   
Income from Continuing Operations (in dollars per share)5.714.861.78
Income from Discontinued Operations (in dollars per share)00.281.00
Net Income (in dollars per share)$ 5.71$ 5.14$ 2.78

MRK Balance Sheet

2022-12-31
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents$ 12,694$ 8,096
Short-term investments4980
Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)9,4509,230
Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note 8)5,9115,953
Other current assets7,1696,987
Total current assets35,72230,266
Investments1,015370
Property, Plant and Equipment (at cost)  
Land295326
Buildings13,16612,529
Machinery, equipment and office furnishings16,76016,303
Construction in progress9,1868,313
Property, plant and equipment (at cost)39,40737,471
Less: accumulated depreciation17,98518,192
Property, plant and equipment, net21,42219,279
Goodwill21,20421,264
Other Intangibles, Net20,26922,933
Other Assets9,52811,582
Total Assets109,160105,694
Current Liabilities  
Loans payable and current portion of long-term debt1,9462,412
Trade accounts payable4,2644,609
Accrued and other current liabilities14,15913,859
Income taxes payable1,9861,224
Dividends payable1,8841,768
Total current liabilities24,23923,872
Long-Term Debt28,74530,690
Deferred Income Taxes1,7953,441
Other Noncurrent Liabilities8,3239,434
Merck & Co., Inc. Stockholders’ Equity  
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 20211,7881,788
Other paid-in capital44,37944,238
Retained earnings61,08153,696
Accumulated other comprehensive loss(4,768)(4,429)
Stockholders' equity before deduction for treasury stock102,48095,293
Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 202156,48957,109
Total Merck & Co., Inc. stockholders’ equity45,99138,184
Noncontrolling Interests6773
Total equity46,05838,257
Total Liabilities and Equity$ 109,160$ 105,694